Takeda to sell Techpool to Chinese JV partners
The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE
China’s National Medical Products Administration (NMPA) has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis.
The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across